Diabetes Intelligence Hub — Pakistan

Pakistan has one of the fastest-growing diabetes burdens in South Asia. This hub maps the medicine landscape — key molecules, competing brands, price positioning versus official DRAP ceilings, and the gaps where a new entrant can make a difference.

Diabetes in Pakistan

29,469
Medicine pages in catalog
10
Key diabetes molecules tracked
15
Companies with diabetes brands
1318
Total companies mapped

Data as of 2026-07-30. Prices are observed retail / official ceilings — not sales volumes. All figures are demand proxies, not real sales. See the full market intelligence dashboard for opportunity scoring across categories.

Key Molecules

Metformin
First-line therapy
Essential medicine
Price range: Rs 16Rs 3,300
Glimepiride
Sulfonylurea — insulin secretagogue
Price range: Rs 60.6Rs 1,266.98
Sitagliptin
DPP-4 inhibitor
Price range: Rs 139.65Rs 1,899.94
Empagliflozin
SGLT2 inhibitor — cardio-renal benefit
Essential medicine
Price range: Rs 19Rs 3,343.8
Dapagliflozin
SGLT2 inhibitor
Essential medicine
Price range: Rs 101.64Rs 3,189.07
Pioglitazone
Thiazolidinedione — insulin sensitizer
Price range: Rs 104.51Rs 2,841.27
Gliclazide
Sulfonylurea — shorter half-life
Essential medicine
Price range: Rs 114.76Rs 3,243.33
Insulin Glargine
Long-acting basal insulin
Essential medicine
No retail price in catalog
Insulin Lispro
Rapid-acting meal insulin
Essential medicine
No retail price in catalog
Glibenclamide
Sulfonylurea — older generation
Essential medicine
Price range: Rs 30.3Rs 313.8

Brand & Company Map

Top companies by diabetes brand count in the catalog.

CompanyBrandsMolecules
GETZ PHARMA PAKISTAN (PVT) LTD.8628 distinct
HILTON PHARMA (PVT) LIMITED7119 distinct
CCL Pharmaceuticals (Pvt.) Ltd.3812 distinct
AGP (PRIVATE) LTD.3611 distinct
PharmEvo Private Limited3419 distinct
NABIQASIM INDUSTRIES (PVT) LTD.3322 distinct
Martin Dow Pharmaceuticals (Pvt) Ltd.2916 distinct
Ferozsons Laboratories Limited2913 distinct
MACTER INTERNATIONAL (PVT) LTD.2912 distinct
SANOFI AVENTIS (PAKISTAN) LTD.279 distinct
Atco Pharma International (Pvt) Ltd2713 distinct
HIGH - Q INTERNATIONAL2610 distinct
HIGHNOON LABORATORIES LIMITED249 distinct
Martin Dow Marker Limited2412 distinct
Genix Pharma Private Limited2212 distinct

Price Landscape vs DRAP Ceilings

Retail price range per molecule (DVAGO observed + DRAP official ceiling).

Metformin
Retail (DVAGO):Rs 16 – Rs 496.86
DRAP ceiling:Rs 504.42
Empagliflozin
Retail (DVAGO):Rs 19 – Rs 499.98
DRAP ceiling:Rs 501.62
Glibenclamide
Retail (DVAGO):Rs 30.3 – Rs 313.8
DRAP ceiling:No ceiling on record
Glimepiride
Retail (DVAGO):Rs 60.6 – Rs 474.29
DRAP ceiling:Rs 506.46
250
Retail (DVAGO):Rs 85.07 – Rs 88.33
DRAP ceiling:No ceiling on record
500
Retail (DVAGO):Rs 85.07 – Rs 392.42
DRAP ceiling:No ceiling on record
Metfromin
Retail (DVAGO):Rs 85.07 – Rs 88.33
DRAP ceiling:No ceiling on record
Ibuprofen
Retail (DVAGO):Rs 85.12 – Rs 85.12
DRAP ceiling:No ceiling on record
Glimepiride.................................2Mgmetforminhcl........................500Mg
Retail (DVAGO):Rs 100.3 – Rs 316.75
DRAP ceiling:No ceiling on record
Glimepride.........1Mg
Retail (DVAGO):Rs 100.3 – Rs 316.75
DRAP ceiling:No ceiling on record
Dapagliflozin
Retail (DVAGO):Rs 101.64 – Rs 488.6
DRAP ceiling:Rs 503.58
Sodium
Retail (DVAGO):Rs 102.65 – Rs 159.94
DRAP ceiling:No ceiling on record

Partner Slots — Scarcity Is the Product

ANCHORExclusive

Anchor Partner

PKR 500k–1M/month (pilot ~200–300k)
  • Top placement on every hub page
  • Verified education content — your logo on every page
  • Quarterly category report included
  • First-mover reference customer pricing
Scarcity: 1 slot — first anchor sold at pilot pricing; renewals repriced against waitlist
EDUCATION PARTNER

Verified Education Partner

PKR 100–200k/month
  • Verified product pages within the hub
  • Named placement in partner directory
  • Link to your product pages from molecule panels
Scarcity: 3 slots — 1 remaining
Request Pilot Access WhatsApp us pilot pricing available

Awareness Content

Understanding Diabetes in Pakistan

Pakistan has an estimated 33 million people living with diabetes — one of the highest prevalence rates in South Asia. Type 2 diabetes accounts for the vast majority of cases, driven by rapid urbanisation, dietary changes, and sedentary lifestyles.

Early diagnosis and consistent medication adherence are the two most impactful levers for reducing complications. The molecules tracked in this hub represent the standard treatment pathway from first-line (metformin) through second-line (SGLT2 inhibitors, GLP-1 receptor agonists) to insulin therapy.

Price Sensitivity & Access

The majority of Pakistani diabetes patients pay out-of-pocket. DRAP official ceilings set the legal maximum, but actual retail prices vary significantly across sources — DVAGO, Servaid, and DRAP-official pricing can differ by 2–10x for the same molecule.

This price spread creates both opportunity and risk: patients who cannot afford branded products may default to substandard alternatives, while companies with competitive pricing can capture significant market share.

Data as of 2026-07-30 · schema v3-SKU · sources: drap_prices, drap_registry, dvago_alphabet, dvago_full, servaid, drap_alerts.

For pharmaceutical intelligence and professional reference only. Not medical advice. Partner slot pricing is pilot-rate and subject to change.